WO2025224506 - METHODS FOR REDUCING PLATELET DEGRADATION USING FCRN ANTAGONISTS
National phase entry is expected:
Publication Number
WO/2025/224506
Publication Date
30.10.2025
International Application No.
PCT/IB2025/000186
International Filing Date
22.04.2025
Title **
[English]
METHODS FOR REDUCING PLATELET DEGRADATION USING FCRN ANTAGONISTS
[French]
PROCÉDÉS DE RÉDUCTION DE LA DÉGRADATION DES PLAQUETTES À L'AIDE D'ANTAGONISTES DE FCRN
Applicants **
ARGENX BV
Inventors
ULRICHTS, Peter
GODAR, Marie
HULTBERG, Anna
MATTHIJSSENS, Filip
Priority Data
63/637,161
22.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3679 | |
| EPO | Filing, Examination, Granting | 39956 | |
| Japan | Filing, Examination, Granting | 3542 | |
| South Korea | Filing, Examination, Granting | 4885 | |
| USA | Filing, Examination, Granting | 16340 |
Total:
68,402
Contact Us
Abstract[English]
Provided herein are methods of reducing platelet degradation in a subject in need thereof, such as a subject that has immune thrombocytopenia (ITP), using an antagonist of human neonatal Fc receptor (FcRn), which in certain embodiments is efgartigimod.[French]
L'invention concerne des procédés de réduction de la dégradation des plaquettes chez un sujet en ayant besoin, tel qu'un sujet atteint d'une thrombocytopénie immunitaire (ITP), à l'aide d'un antagoniste du récepteur Fc néonatal humain (FcRn), qui dans certains modes de réalisation est l'efgartigimod.